EBV-specific T Cells As Therapy For Relapsed - Refractory EBV-positive Lymphomas
Funder
National Health and Medical Research Council
Funding Amount
$324,397.00
Summary
The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.